Viloxazine
Viloxazine is a norepinephrine reuptake inhibitor originally developed as an antidepressant that has gained approval for the treatment of attention-deficit/hyperactivity disorder (ADHD). It provides a non-stimulant option for managing ADHD symptoms, making it suitable for patients who may not tolerate or respond well to stimulant medications.
Viloxazine is a norepinephrine reuptake inhibitor used to treat ADHD, originally developed as an antidepressant.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- N06AX09
- RxNorm
- 11196
- Generic
- Viloxazine
- Class
- atc-n06
- Brands
- Qelbree
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 200mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 200mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless potential benefits justify potential risks to the fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
use only if clearly needed, weigh risks and benefits carefully
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
discontinue use near term if possible, discuss with healthcare provider
fetal monitoring and assessment for neonatal effects
Use with caution and monitor for adverse effects.
lactation
breastfeedingdiscontinue breastfeeding or discontinue drug
vilyoxazine is likely excreted in breast milk, breastfeeding not recommended during treatment
monitor infant for adverse effects
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children 6 to 11 yearsweight-based dosing, start low
approved for ADHD in patients 6-17 years, starting dose 50mg once daily, may increase to 100mg
monitor growth, weight, and blood pressure
pediatric_age
adolescents 12 to 17 yearsstandard adult dosing may be used
approved for ADHD, starting dose 50mg once daily, may increase to 200mg maximum
monitor blood pressure, heart rate, and psychiatric symptoms
geriatric
elderly 65 years and olderstart at lowest effective dose
use with caution, limited clinical experience in elderly population, monitor for orthostatic hypotension
monitor blood pressure, renal function, and for adverse effects
Use with caution and monitor for adverse effects.
renal_impairment
mild renal impairmentno dose adjustment typically required
use with caution, monitor renal function periodically
periodic renal function monitoring
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentdose reduction recommended
reduce dose to minimum effective dose, avoid use in end-stage renal disease
close monitoring of renal function and drug levels if available
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderate hepatic impairmentno specific dose adjustment in mild impairment
use with caution, start at lower dose
monitor liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
severe hepatic impairmentreduce dose significantly
use with extreme caution, limited data available
close monitoring of liver function and clinical response
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Viloxazine is a non-stimulant ADHD medication classified as an SNRI
FDA approval year
FDA approved Viloxazine (Qelbree) for ADHD treatment
Primary indication
Approved for treatment of ADHD in pediatric patients ages 6-17
Brand name
Commercial brand name for Viloxazine
Viloxazine is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Originally developed as an antidepressant, it has received approval for ADHD management in applicable regions.
The precise mechanism by which viloxazine exerts its therapeutic effect in ADHD is not fully elucidated; however, it is believed to function by inhibiting the reuptake of norepinephrine, thereby increasing norepinephrine availability in the brain.
Viloxazine should be used under medical supervision. Patients should disclose their complete medical history and all current medications to their healthcare provider before initiating treatment. Side effects may include somnolence, fatigue, headache, and decreased appetite. Its non-stimulant classification offers an alternative for patients who cannot tolerate stimulant-based ADHD treatments.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy